Exploration of *Aspergillus fumigatus* Ras pathways for novel antifungal drug targets

Qusai Al Abdallah and Jarrod R. Fortwendel*

Department of Microbiology and Immunology, University of South Alabama, Mobile, AL, USA

Ras pathway signaling is a critical virulence determinant for pathogenic fungi. Localization of Ras to the plasma membrane (PM) is required for Ras network interactions supporting fungal growth and virulence. For example, loss of *Aspergillus fumigatus* RasA signaling at the PM via inhibition of palmitoylation leads to decreased growth, altered hyphal morphogenesis, decreased cell wall integrity and loss of virulence. In order to be properly localized and activated, Ras proteins must transit a series of post-translational modification (PTM) steps. These steps include farnesylation, proteolytic cleavage of terminal amino acids, carboxymethylation, and palmitoylation. Because Ras activation drives tumor development, Ras pathways have been extensively studied in mammalian cells as a potential target for anti-cancer therapy. Inhibitors of mammalian Ras interactions and PTM components have been, or are actively being, developed. This review will focus on the potential for building upon existing scaffolds to exploit fungal Ras proteins for therapy, synthesizing data from studies employing both mammalian and fungal systems.

**Keywords:** Ras protein, G domain, hypervariable region, post-translational modifications, spatio-temporal regulation, fungal pathogenesis, antifungal therapeutics

**INTRODUCTION**

*Aspergillus fumigatus* is the most common fungal pathogen of invasive aspergillosis in immunocompromised patients. Despite the introduction of several antifungal drugs, infections related to invasive aspergillosis are usually severe and fatal (Latge, 1999). Therefore, there is an increasing demand for new drugs against *A. fumigatus* infections, and thereby identification of target proteins as targets for antifungal therapeutics.

Ras-mediated signaling pathways play key roles in regulating cell responses to different stresses via a wide range of effector proteins (for more information, refer to Rajalingam et al., 2007). In pathogenic fungi, Ras signaling pathways control virulence in host cells (reviewed in detail in Fortwendel, 2012). Therefore Ras proteins, and their effectors, represent potential targets of intervention for novel antifungal therapies. Due to their role in tumor formation, mammalian Ras post-translational modification (PTM) pathway proteins have been studied in detail for their potential as targets for anticancer therapeutics (refer to Downward, 2003; Adjei and Hidalgo, 2005; Spiegel et al., 2014). In this minireview, we discuss these studies in the context of development of antifungal therapy. Since RasA is the major Ras protein in *A. fumigatus*, this brief review focuses on the RasA signaling pathway.

**A. Fumigatus Ras PROTEINS**

Ras proteins are low molecular weight monomeric G-proteins, which localize to the plasma membrane (PM) and exhibit GTase activities (Wennenber et al., 2005). They are induced by extracellular stimuli and function primarily as signal mediators for several downstream cascades. Such cascades activate transcription factors, which control a wide range of cellular processes such as cell growth, division, differentiation and survival (Weeks and Spiegelman, 2003). In contrast to human cells, which typically express three Ras isoforms (HRas, KRas, and NRas), only two Ras homologs (RasA and RasB) are produced in *A. fumigatus* (Fortwendel et al., 2004). Based on sequence similarity, RasA is more closely related to the human H-Ras with homologs found in most eukaryotes. In contrast, RasB is only produced by filamentous fungi (Fortwendel et al., 2004). Both, RasA, and RasB, exhibit distinct but overlapping roles in conidial germination, mycelial growth, conidiogenesis, and cell mitosis (Fortwendel et al., 2004, 2005, 2008, 2012). Additionally, both proteins modulate virulence in *A. fumigatus* and other pathogenic fungi (Fortwendel et al., 2005, 2012; Fortwendel, 2012).

**DOMAIN STRUCTURE OF Ras PROTEINS**

The domain structure of human Ras proteins has been reviewed in detail previously (Sprang, 1997; Vetter and Wittinghofer, 2001; Wittinghofer and Vetter, 2011). Briefly, the approximately 190-amino acid protein is divided into 165 highly conserved amino acids (90–100% identical) at the N-terminus (known as the G domain or GTase domain) and a C-terminal hypervariable region (HVR) that encompasses the remaining amino acids (Hancock, 2003). In the next sections, we will discuss the domain structure of both regions and their role in mediating Ras activation, transmembrane localization and cell signaling.

**THE G DOMAIN FACILITATES PROTEIN CONFIRMATION AND DOWNSTREAM SIGNALING**

Numerous biochemical, molecular and structural studies, involving both yeast and mammalian cells, have shown that the
G domain of Ras-like proteins houses the amino acid sequences required for binding guanine nucleotides [i.e., guanosine diphosphate (GDP) and guanosine triphosphate (GTP)], GTPase-activating protein (GAP), guanine nucleotide exchange factor (GEF), and downstream effectors (Ahearn et al., 2012). The G domain is organized into six β sheets and five α helices. Additionally, two loop regions, designated switch I and switch II, mediate Ras transformation between its two interchangeable activity states via conformational change during binding of guanine nucleotides (Vetter and Wittinghofer, 2001).

The Ras activation mechanism involves GEF proteins, which promote the release of GDP. GTP, which exists in the cytoplasm at concentrations 10 times higher than that of GDP, binds to the GDP-free form of Ras. GTP association with Ras releases energy, which changes protein conformation at the switch I and II regions. This transforms Ras to the active state and allows binding of the effector proteins to its G domain. Active Ras proteins are negatively regulated by GAP proteins. Binding of GAP to Ras protein increases its intrinsic GTPase activity $10^5$ fold and hydrolyzes GTP to GDP. The hydrolysis of GTP depletes the released energy, causing conformational changes at the switch domains, and subsequently releasing the effector (Vetter and Wittinghofer, 2001; Wennerberg et al., 2005; Kyriakis, 2009; Ahearn et al., 2012; Prior and Hancock, 2012).

### THE HVR GOVERNS Ras MEMBRANE LOCALIZATION AND ANCHORING

The HVR of RasA homologs is divided into two regions: an anchor and a linker. The anchor region is highly conserved among Ras isoforms and is composed of a CAAX box—where C is cysteine, AA are two aliphatic amino acids, and X is any amino acid—and a palmitoylation motif (Gao et al., 2009).

The anchor plays an essential role in Ras subcellular trafficking and membrane localization. Protein trafficking and subsequent membrane association of many proteins is typically mediated by hydrophobic transmembrane domains. However, Ras proteins lack such domains, and therefore the protein undergoes several PTMs at the CAAX box and the palmitoylated cysteine motif which convert the HVR to a hydrophobic, membrane-associated domain (Figure 1A) (Takai et al., 2001; Hancock, 2003; Larsen et al., 2006; Iwasaki and Ōmura, 2007).

Ras PTM mechanisms have been studied in detail in human and yeast cells. In spite of lack of similar studies in Aspergillus fumigatus and other filamentous fungi such as S. pombe and Candida albicans; to two cysteine residues in Cryptococcus neoformans and other filamentous fungi such as A. fumigatus. Second, variations in the anchor region might exist between different Ras homologs within one fungal species. For example, unlike RasA, A. fumigatus RasB does not contain the palmitoylation cysteine residues. Although no experimental evidence for RasB localization exists, the differences in anchor region amino acid sequence might indicate different subcellular localizations of RasA and RasB (Fortwendel, 2012).

### Ras-MEDIATED FUNGAL MORPHOGENESIS AND VIRULENCE DEPEND ON THE SPATIO-TEMPORAL REGULATION OF Ras ACTIVITY

Like their human counterparts, the cellular functions of fungal Ras GTPases depend on the spatio-temporal regulation of the protein on the PM. Understanding the spatio-temporal organization of RasA has been a necessary step in selecting potential targets that are predicted to interfere with its ability to properly transmit signals for growth, stress response and virulence. The following sections will briefly summarize our current knowledge of RasA spatial and temporal regulation mechanisms.

### THE TEMPORAL REGULATION OF RasA ACTIVITY

The essential role of temporal activation of RasA has been investigated by comparing the phenotype of A. fumigatus mutants that express dominant negative RasA (DNRasA) or dominant activate RasA (DARasA) to that of a rasA ($\Delta$rasA) deletion mutant. The DNRasA and DARasA mutants provide the ability to study the phenotypic effects of improper temporal inactivation or activation of RasA, respectively, during development. DNRasA, and $\Delta$rasA strains show similar phenotypes (i.e., delayed in germination), whereas the DARasA mutant initiates germination in the absence
of a germinant. Additionally, mycelia of all three strains grow slower than wild type and exhibit defects in polarity maintenance. Although constitutive Ras activation delays germ tube formation and reduces colony outgrowth, the DArasA mutant also displays hyphal swelling and spontaneous lysis during fully polarized growth (Fortwendel, 2012). These data show the importance of temporal regulation of RasA activity for proper hyphal morphogenesis, since the inability to modulate RasA activity during developmental progression causes abnormalities in fungal growth.

THE SPATIAL REGULATION OF RasA SIGNALING

In addition to the previously described temporal regulation, spatial regulation of Ras signaling plays an essential role in RasA function. Evidence for the cellular mechanisms that control A. fumigatus RasA PTM and localization was obtained from subcellular localization analyses of RasA using GFP tagging. Similar to human Ras, RasA localizes to the PM of A. fumigatus. However, when RasA farnesylation is blocked by exchange mutagenesis of the CAAX box cysteine residue (C210) to serine, RasA aborts the PM localization and accumulates in the cytoplasm. Additionally, expression of RasA in an A. fumigatus deletion strain of the putative palmitoyltransferase subunit gene (ΔerfD) shows a punctate localization of RasA, implying palmitoylation of RasA is required for PM localization. Furthermore, mutation of the palmitoylation double cysteine motif (C206 and C207) to serine mislocalizes RasA to endomembranes. Phenotype analysis of these mutants showed that A. fumigatus strains expressing either a non-farnesylated or non-palmitoylated
RasA exhibit a full or partial ΔrasA phenotype, respectively (Fortwendel et al., 2012; Norton and Fortwendel, 2014). Consistent with these data, similar results have been obtained in other pathogenic fungi. For example, in C. neoformans, farnesylation and palmitoylation are both required for normal Ras1 localization and morphogenesis (Nichols et al., 2009). In C. albicans, both PTMs are required for localization, but farnesylation plays the greater role in Ras-mediated growth and morphogenesis (Piispanen et al., 2011). Taken together, these data support the importance of RasA PTM processes for fungal growth and virulence.

APPROACHES FOR DEVELOPING Ras-TARGETED ANTIFUNGAL THERAPEUTICS

Mammalian Ras signaling pathways have been the target of extensive research for developing anticancer therapeutics. This accumulated knowledge could be translated into novel strategies to treat Aspergillus infections since the mechanisms of Ras activation and PTMs are shared by both human and fungi. The development of Ras-targeted anticancer therapy has focused on: (1) targeting Ras proteins directly, (2) blockade of Ras upstream and downstream signaling pathways, and (3) inhibition of Ras PTMs. There are many Ras inhibitors that have tested in mammalian cell as anticancer therapeutics. Details on specific successes and failures have been reviewed extensively (Adjei and Hidalgo, 2005; Berndt et al., 2011; Spiegel et al., 2014). Although all three of these have been pursued as potentially viable channels for inhibition of Ras function, most progress has been achieved in the development of anti-Ras compounds targeting the PTM pathway. In the following section, we will briefly describe these approaches, focusing mainly on inhibition of Ras PTMs and the published data that support this pathway as a potential anti-Aspergillus therapeutic target.

TARGETING Ras PROTEINS AND Ras PROTEIN INTERACTIONS

In A. fumigatus, RasA modulates fungal pathogenesis and has been considered an attractive target for antifungal agents. Directly targeting Ras proteins for anticancer therapies has proven a difficult task. For example, inhibition of Ras-GTP binding is difficult to achieve, since the Ras-GTP interaction is very high affinity, occurring in the picomolar range (Gysin et al., 2011). However, recent approaches have generated small molecules that inhibit K-Ras activation (Maurer et al., 2012). This method relied on in-depth structural analyses of the K-Ras protein, the level of which have not been accomplished for any fungal Ras protein. As such, the applicability of such inhibitors remains unknown for fungal Ras proteins.

In general, fungal Ras proteins appear to share similar signaling mechanisms with their human homologs, and therefore inhibitors of these signaling events might also have great potential for thwarting invasive fungal infections. Examples of these are protein kinases that modulate downstream Ras signaling pathways. Several kinase inhibitors have been applied successfully to treat cancer (reviewed in detail by Downward, 2003), however, these molecules have not been tested in models of fungal infection. Although the signaling mechanisms are similar between humans and fungi, a deeper understanding of the biochemistry underpinning Ras-mediated signaling in pathogenic fungi is required for the identification of fungal-specific, selective targets in this area.

INHIBITION OF Ras PTM

Inhibition of farnesylation

In contrast to the limited number of therapeutics directly targeting Ras proteins, multiple compounds are being developed and employed to inhibit steps in the PTM pathway of human Ras proteins. Importantly, the individual elements of the PTM pathway are conserved between humans and fungal pathogens, the first step of which is the lipidation of Ras with a farnesyl moiety (Figure 1B). There are several farnesyl transferase inhibitors (FTIs) that are used or being clinically tested for use as anticancer agents (described in detail by Appels et al., 2005). The antifungal activities of some of these FTIs have been evaluated against several pathogenic fungi. For example, when the wild type strain of C. neoformans was treated with six different FTIs, one inhibitor, i.e., Manumycin A, showed inhibitory activities comparable to Amphotericin B—an antifungal agent. Additionally, when a C. neoformans mutant that lacks the cell wall capsule, i.e., cap59 mutant, was used, two additional FTIs, namely ethylenediamine inhibitor #2 and tipifarnib, showed elevated inhibitory activities. Interestingly, treatment of C. neoformans with high concentrations of Manumycin A caused a shift in Ras1 localization from the PM to the cytosol (Hast et al., 2011). Similar experiments have been carried out to study antifungal activities of Manumycin A against several species from Aspergillus and Candida. Compared to C. neoformans, the FTI minimal inhibitory concentrations (MIC) were 80–160-fold and 5–10-fold higher for Aspergillus and for Candida, respectively. (Hast et al., 2011; Qiao et al., 2013). However, it is unclear whether such differences in MIC are caused by fungal resistance to Manumycin A; or variations in experimental procedure, media composition, or pH of the media. In a similar experiment, the inhibition of protein farnesylation in C. albicans by farnesyl transferase inhibitor III (FPT inhibitor III) blocked the development of yeast to hyphae (McGeady et al., 2002), which is a Ras-mediated virulence step (Cutler, 1991; Feng et al., 1999). Additionally, FPT Inhibitor III blocks hyphal differentiation in a dose-dependent manner in C. neoformans (Vallim et al., 2004).

To better understand the protein–protein interactions between FT and their inhibitors (FTIs), structural studies of inhibitor-bound A. fumigatus and C. neoformans FT were compared to their human homolog. These studies revealed that the substrate-binding groove residues are highly conserved between human and fungal FT, while the product exit groove displays a high sequence divergence. Importantly, these studies reveal fungal-specific attributes of the highly conserved Ras PTM pathway. For example, both grooves are wider in fungal FT in comparison to their human homolog, causing weaker binding activities of inhibitors toward Aspergillus FT in comparison to human FT (Hast et al., 2011; Mabanglo et al., 2014). Therefore, modification of anticancer FTIs is required for optimal antifungal efficiency. Re-purposing FTIs developed for anticancer treatments may represent a novel area for antifungal drug development.

In addition to targeting Ras farnesylation, mapping the fungal farnesylome, i.e., proteins that are farnesylated by
farnesyltransferase, will open the door for numerous potential drug targets. One example is the Ras-related protein, Rheb, which is, like Ras proteins, farnesylated before transmembrane localization (Clark et al., 1997). The cellular functions of mammalian Rheb are inhibited by cell treatment with FTI (Castro et al., 2003). In A. fumigatus, the Rheb homolog, RhbA, plays an important role in fungal pathogenesis and vegetative growth. An A. fumigatus rhbA deletion mutant, ΔrhbA, exhibits impaired virulence in mouse model and reduced growth on minimal media supplemented with poor nitrogen sources. Additionally, this strain displays higher sensitivity to the rapamycin antibiotic, which inhibits TOR kinases (Panepinto et al., 2003). Taken together, this suggests that fungal Rheb, i.e., Rhb, could serve as potential target for antifungal therapy.

Inhibition of palmitoylation
Palmitoylation is another putative target for antifungal therapeuticst since RasA palmitoylation is important for mycelial polarized growth and virulence. Targeting Ras palmitoylation is still at the beginning stages as an anticancer therapeutic. Palmitoylation inhibitors have only recently been developed and have not yet been employed in disease models (reviewed in Chavda et al., 2014). To our knowledge, only one study assessed the potential of inhibition of RasA palmitoylation as antifungal target. In this study, blocking RasA palmitoylation in A. fumigatus by 2-bromopalmitate disrupts RasA transmembrane localization and reduces fungal growth in liquid culture (Fortwendel et al., 2012). Therefore, additional studies that aim at designing, developing and assessing novel compounds that target fungal RasA palmitoylation are warranted.

CONCLUSION
The potential for developing antifungal therapeutics by targeting the Ras signaling pathway is a promising avenue of research. Ras signaling has been studied intensively in humans, and the accumulated knowledge can be utilized as a scaffold for the development of antifungal agents with selective toxicity. In this study, the individual components of the Ras PTM pathway share only partial sequence similarity with their human homologs (Figure 1B). Additionally, further characterization of Ras regulatory pathways in pathogenic fungi is necessary to deepen our understanding of fungal growth and virulence.

ACKNOWLEDGMENT
This work is supported by NIH grant 5R01AI106925 to JRF.

REFERENCES
Adjei, A. A., and Hidalgo, M. (2005). Intracellular signal transduction pathway proteins as targets for cancer therapy. J. Clin. Oncol. 23, 5386–5403. doi: 10.1200/JCO.2005.23.648
Ahearn, I. M., Haigis, K., Bar-Sagi, D., and Philips, M. R. (2012). Regulating the regulator: post-translational modification of RAS. Nat. Rev. Mol. Cell Biol. 13, 39–51. doi: 10.1038/nrm3255
Appels, N. M., Beijnen, J. H., and Schellens, J. H. M. (2005). Development of farnesyl transferase inhibitors: a review. Oncologist 10, 565–578. doi: 10.1634/theoncologist.10-8-565
Berndt, N., Hamilton, A. D., and Sebit, S. M. (2011). Targeting protein prenylation for cancer therapy. Nat. Rev. Cancer 11, 775–791. doi: 10.1038/nrc3151
Berndt, N., and Sebit, S. M. (2011). Measurement of protein farnesylation and geranylgeranylation in vitro, in cultured cells and in biopsies, and the effects of prenyl transferase inhibitors. Nat. Protec. 6, 1775–1791. doi: 10.1038/nprot.2011.387
Castro, A. F., Rebhun, J. F., Clark, G. L., and Quilliam, L. A. (2003). Rheb binds tuberous sclerosis complex 2 (TSC2) and promotes S6 kinase activation in a rapamycin- and farnesylation-dependent manner. J. Biol. Chem. 278, 32493–32496. doi: 10.1074/jbc.C300226200
Chavda, B., Arnott, J. A., and Planey, S. L. (2014). Targeting protein palmitoylation: selective inhibitors and implications in disease. Expert Opin. Drug Discov. 9, 1005–1019. doi: 10.1517/174604414.2014.933802
Chiu, V. K., Silletti, J., Dinsell, V., Wiener, H., Loukeris, K., Ou, G., et al. (2004). Carboxyl methylation of Ras regulates membrane targeting and effector engagement. J. Biol. Chem. 279, 7346–7352. doi: 10.1074/jbc.M311602200
Clark, G. J., Kinch, M. S., Rogers-Graham, K., Sebit, S. M., Hamilton, A. D., and Der, C. J. (1997). The Ras-related protein rheb is farnesylated and antagonizes Ras signaling and transformation. J. Biol. Chem. 272, 10608–10615. doi: 10.1074/jbc.272.16.10608
Cutler, J. E. (1991). Putative virulence factors of Candida albicans. Annu. Rev. Microbiol. 45, 187–218. doi: 10.1146/annurev.mi.45.100191.001155
Downward, J. (2003). Targeting Ras signalling pathways in cancer therapy. Nat. Rev. Cancer 3, 11–22. doi: 10.1038/nrc696
Feng, Q., Summers, E., Guo, B., and Fink, G. (1999). Ras signaling is required for serum-induced hyphal differentiation in Candida albicans. J. Bacteriol. 181, 6339–6346.
Fortwendel, J. R. (2012). Ras-mediated signal transduction and virulence in human pathogenic fungi. Fungal Genomics Biol. 2, 105. doi: 10.4172/2165-8056.1000105
Fortwendel, J. R., Fuller, K. K., Stephens, T. J., Bacon, W. C., Askew, D. S., and Rhodes, J. C. (2008). Aspergillus fumigatus RasA regulates asexual development and cell wall integrity. Eukaryot. Cell 7, 1530–1539. doi: 10.1112/E.C.00080-08
Fortwendel, J. R., Juvvadi, P. R., Rogg, L. E., Asfaw, Y. G., Burns, K. A., Randell, S. H., et al. (2012). Plasma membrane localization is required for RasA-mediated polarized morphogenesis and virulence of Aspergillus fumigatus. Eukaryot. Cell 11, 966–977. doi: 10.1112/E.C.00091-12
Fortwendel, J. R., Panepinto, J. C., Seitz, A. E., Askew, D. S., and Rhodes, J. C. (2004). Aspergillus fumigatus rasA and rasB regulate the timing and morphology of asexual development. Fungal Genet. Biol. 41, 129–139. doi: 10.1016/j.fgb.2003.10.004
Fortwendel, J. R., Zhao, W., Bhabhra, R., Park, S., Perlín, D. S., Askew, D. S., et al. (2005). A fungus-specific Ras homolog contributes to the hyphal growth and virulence of Aspergillus fumigatus. Eukaryot. Cell 4, 1982–1989. doi: 10.1112/E.C.12.1982.1989.2005
Gao, J., Liao, J., and Yang, G.-Y. (2009). CAAX-box protein, prenylation process and carcinogenesis. Am. J. Transl. Res. 1, 312–325.
Goodwin, J. S., Drake, K. R., Rogers, C., Wright, L., Lippincott-Schwartz, J., Philips, M. R., et al. (2005). Depalmitoylated Ras traffics to and from the Golgi complex via a non-vesicular pathway. J. Cell. Biol. 170, 261–272. doi: 10.1083/jcb.200502063
Greaves, J., and Chamberlain, L. H. (2007). Palmitoylation-dependent protein sorting. J. Cell. Biol. 176, 249–254. doi: 10.1083/jcb.200610151
Gysin, S., Salt, M., Young, A., and McCormick, F. (2011). Therapeutic strategies for targeting Ras proteins. Genes Cancer 2, 359–372. doi: 10.1177/1947601911412376
Hancock, J. F. (2003). Ras proteins: different signals from different locations. Nat. Rev. Mol. Cell Biol. 4, 373–385. doi: 10.1038/nrm1105
Hancock, J. F., Magee, A. I., Childs, J. E., and Marshall, C. J. (1989). All ras proteins are polyisoprenylated but only some are palmitoylated. Cell 57, 1167–1177. doi: 10.1016/0022-8476(89)90054-8
Hancock, J. F., Paterson, H., and Marshall, C. J. (1990). A polybasic domain or palmitoylation is required in addition to the CAAX motif to localize p21ras to the plasma membrane. Cell 63, 133–139. doi: 10.1002/0092-8674/900924-O
Hast, M. A., Nichols, C. B., Armstrong, S. M., Kelly, S. M., Hellinga, H. W., Alspaugh, J. A., et al. (2011). Structures of Cryptococcus neoformans protein farnesyltransferase reveal strategies for developing inhibitors that target fungal pathogens. J. Biol. Chem. 286, 35149–35162. doi: 10.1074/jbc.M111.250506
Iwasaki, S., and Ōmura, S. (2007). Search for protein farnesyltransferase inhibitors of microbial origin: our strategy and results as well as the results obtained by other groups. J. Antibiot. (Tokyo) 60, 1–12. doi: 10.1038/ja.2007.1
Kyrkiakis, J. M. (2009). Thinking outside the box about Ras. J. Biol. Chem. 284, 10993–10994. doi: 10.1074/jbc.R800085200

Larsen, M. R., Trelle, M. B., Thingholm, T. E., and Jensen, O. N. (2006). Analysis of post-translational modifications of proteins by tandem mass spectrometry. Biotechniques 40, 790–798. doi: 10.2144/000112201

Lagte, J.-P. (1999). Aspergillus fumigatus and aspergillosis. Clin. Microbiol. Rev. 12, 310–350.

Linder, M. E., and Deschenes, R. J. (2007). Palmitoylation: policing protein stability and traffic. Nat. Rev. Mol. Cell Biol. 8, 74–84. doi: 10.1038/nrm2084

Mabanglo, M. F., Hast, M. A., Lubock, N. B., Hellinga, H. W., and Beece, L. S. (2014). Crystal structures of the fungal pathogen Aspergillus fumigatus protein farnesyltransferase complexed with substrates and inhibitors reveal features for antifungal drug design. Protein Sci. 23, 289–301. doi: 10.1002/pro.2411

Manolaridis, I., Kulkarni, K., Dodd, R. B., Ogasawara, S., Zhang, Z., Bineva, G., et al. (2013). Mechanism of farnesylated CAAX protein processing by the integral membrane protease Rce1. Nature 504, 301–305. doi: 10.1038/nature12754

Maurer, T., Garrenton, L. S., Oh, A., Pitts, K., Anderson, D. J., Skelton, N. J., et al. (2012). Small-molecule ligands bind to a distinct pocket in Ras and inhibit SOS-mediated nucleotide exchange activity. Proc. Natl. Acad. Sci. U.S.A. 109, 5299–5304. doi: 10.1073/pnas.1116510109

McGeady, P., Logan, D. A., and Wansley, D. L. (2002). A protein-farnesyl transferase inhibitor interferes with the serum-induced conversion of Candida albicans from a cellular yeast form to a filamentous form. FEMS Microbiol. Lett. 213, 41–44. doi: 10.1111/j.1574-6968.2002.tb11285.x

Nichols, C. B., Ferreyra, J., Ballou, E. R., and Alspaugh, J. A. (2009). Subcellular localization directs signaling specificity of the Cryptococcus neoformans Ras1 protein. Eukaryot. Cell 8, 181–189. doi: 10.1128/EC.00351-08

Norton, T. S., and Fortwendel, J. R. (2014). Control of Ras-mediated signaling in Aspergillus fumigatus. Mycopathologia 178, 325–330. doi: 10.1007/s11046-014-9765-1

Omerovic, J., Laude, A. J., and Prior, I. A. (2007). Ras proteins: paradigms for compartmentalised and isoform specific signalling. Mol. Cell. Life Sci. 64, 2575–2589. doi: 10.1007/s00018-007-1133-8

Panepinto, J. C., Oliver, B. G., Fortwendel, J. R., Smith, D. L. H., Askew, D. S., and Rhodes, J. C. (2003). Deletion of the Aspergillus fumigatus gene encoding the Ras-related protein RhbA reduces virulence in a model of invasive pulmonary aspergillosis. Infect. Immun. 71, 2819–2826. doi: 10.1128/IAI.71.5.2819-2826.2003

Piispanen, A. E., Bonnefoi, O., Carden, S., Deveau, A., Bassilana, M., and Hogan, D. A. (2011). Roles of Ras1 membrane localization during Candida albicans hyphal growth and farnesol response. Eukaryot. Cell 10, 1473–1484. doi: 10.1128/EC.01533-11

Prior, I. A., and Hancock, J. F. (2012). Ras trafficking, localization and compartmentalised signalling. Semin. Cell Dev. Biol. 23, 145–153. doi: 10.1016/j.semcdb.2011.09.002

Qiao, J., Gao, P., Jiang, X., and Fang, H. (2013). In vitro antifungal activity of farnesyltransferase inhibitors against clinical isolates of Aspergillus and Candida. Ann. Clin. Microbiol. Antimicrob. 12, 37. doi: 10.1186/1476-0711-12-37

Rajalingam, K., Schreck, R., Rapp, U. R., and Albert, Š. (2007). Ras oncogenes and their downstream targets. Biochim. Biophys. Acta 1773, 1177–1195. doi: 10.1016/j.bbamcr.2007.01.012

Salaun, C., Greaves, J., and Chamberlain, L. H. (2010). The intracellular dynamic of protein palmitoylation. J. Cell Biol. 191, 1229–1238. doi: 10.1083/jcb.201008160

Smotrys, J. E., and Wittinghofer, A. (2001). The guanine nucleotide-binding switch in three dimensions. Science 294, 1299–1304. doi: 10.1126/science.1062023

Sprang, S. R. (1997). G PROTEIN MECHANISMS: insights from structural analysis. Annu. Rev. Biochem. 66, 639–678. doi: 10.1146/annurev.biochem.66.1.639

Takai, Y., Sasaki, T., and Matozaki, T. (2001). Small GTP-binding proteins. Eukaryot. Cell 8, 178, 325–330. doi: 10.1007/s11046-014-7133-8

Wan, J., Roth, A. F., Bailey, A. O., and Davis, N. G. (2007). Palmitoylated proteins: purification and identification. Nat. Protoc. 2, 1573–1584. doi: 10.1038/nprot.2007.225

Weeks, G., and Spiegelman, G. B. (2003). Roles played by Ras subfamily proteins in the cell and developmental biology of microorganisms. Cell. Signal. 15, 901–909. doi: 10.1016/S0898-6568(03)00073-1

Wennerberg, K., Rossman, K. L., and Der, C. J. (2005). The Ras-related protein RhbA reduces virulence in a model of invasive pulmonary aspergillosis. Infect. Immun. 73, 2884–2886. doi: 10.1128/IAI.73.5.2884-2886.2005

Conflict of Interest Statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Received: 20 January 2015; accepted: 03 February 2015; published online: 26 February 2015.

Citation: Al Abdallah Q and Fortwendel JR (2015) Exploration of Aspergillus fumigatus Ras pathways for novel antifungal drug targets. Front. Microbiol. 6:128. doi: 10.3389/fmicb.2015.00128

This article was submitted to Fungi and Their Interactions, a section of the journal Frontiers in Microbiology. Copyright © 2015 Al Abdallah and Fortwendel. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.